Histamine improves survival and protects against interleukin-2-induced pulmonary vascular leak syndrome in mice

Vascular Pharmacology

Volumn 42, Issue 4, 2005, Pages 187-193

  Hornyak, Stephen C ^a   Orentas, Diana M ^a   Karavodin, Linda M ^a   Gehlsen, Kurt R ^a  

^a Maxim Pharmaceuticals Inc   (United States)

Author keywords

Histamine; Immunotherapy; Interleukin 2; Reactive oxygen species

Indexed keywords

CYTOKINE; EVANS BLUE; GAMMA INTERFERON; HISTAMINE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAPILLARY LEAK SYNDROME; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; LUNG BLOOD VESSEL; LUNG EDEMA; LUNG INJURY; LUNG WEIGHT; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SURVIVAL RATE;

EID: 16244388978     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vph.2005.02.011     Document Type: Article

References (24)

1. S.S. Agarwala, J. Glaspy, S.J. O'Day, M. Mitchell, J. Gutheil, E. Whitman, R. Gonzalez, E. Hersh, L. Feun, R. Belt, F. Meyskens, K. Hellstrand, D. Wood, J.M. Kirkwood, K.R. Gehlsen, and P. Naredi Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma J. Clin. Oncol. 20 1 2002 125 133
2. S.S. Agarwala, K. Hellstrand, K. Gehlsen, and P. Naredi Immunotherapy with histamine and interleukin 2 in malignant melanoma with liver metastasis Cancer Immunol. Immunother. 53 9 2004 840 841
3. A. Asea, S. Hermodsson, and K. Hellstrand Histaminergic regulation of natural killer cell-mediated clearance of tumour cells in mice Scand. J. Immunol. 43 1 1996 9 15
4. E. Assier, V. Jullien, J. Lefort, J.L. Moreau, J.P. Di Santo, B.B. Vargaftig, J.R. Lapa e Silva, and J. Theze NK cells and polymorphonuclear neutrophils are both critical for IL-2-induced pulmonary vascular leak syndrome J. Immunol. 172 12 2004 7661 7668
5. K.S. Babe Jr., and W.E. Serafin Histamine, bradykinin, and their antagonists Goodman and Gilman's the pharmacological basis of therapeutics 10th ed 2000 McGraw-Hill New York, New York 581 600
6. R. Baluna, and E.S. Vitetta Vascular leak syndrome: a side effect of immunotherapy Immunopharmacology 37 2-3 1997 117 132
7. M. Brune, M. Hansson, U.H. Mellqvist, S. Hermodsson, and K. Hellstrand NK cell-mediated killing of AML blasts: role of histamine, monocytes and reactive oxygen metabolites Eur. J. Haematol. 57 4 1996 312 319
8. F. Donskov, H. von der Maase, R. Henriksson, U. Stierner, P. Wersäll, H. Nellemann, K. Hellstrand, K. Engman, and P. Naredi Outpatient treatment with subcutaneous histamine dihydrochloride in combination with interleukin-2 and interferon-α in patients with metastatic renal cell carcinoma: results of an open, single-armed, multicentre phase-II study Ann. Oncol. 13 3 2002 441 449
9. G. Fyfe, R.I. Fisher, S.A. Rosenberg, M. Sznol, D.R. Parkinson, and A.C. Louie Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy J. Clin. Oncol. 13 3 1995 688 696
10. M. Hansson, S. Hermodsson, M. Brune, U.H. Mellqvist, P. Naredi, A. Betten, K.R. Gehlsen, and K. Hellstrand Histamine protects T cells and natural killer cells against oxidative stress J. Interferon Cytokine Res. 19 10 1999 1135 1144
11. K. Hellstrand, and S. Hermodsson Synergistic activation of human natural killer cell cytotoxicity by histamine and interleukin-2 Int. Arch. Allergy Appl. Immunol. 92 4 1990 379 389
12. K. Hellstrand, A. Asea, and S. Hermodsson Role of histamine in natural killer cell-mediated resistance against tumor cells J. Immunol. 145 12 1990 4365 4370
13. K. Hellstrand, U.H. Mellqvist, E. Wallhult, J. Carneskog, E. Kimby, F. Celsing, and M. Brune Histamine and interleukin-2 in acute myelogenous leukemia Leuk. Lymphoma 27 5-6 1997 429 438
14. K. Hellstrand, M. Brune, C. Dahlgren, M. Hansson, S. Hermodsson, P. Lindner, U.H. Mellqvist, and P. Naredi Alleviating oxidative stress in cancer immunotherapy: a role for histamine? Med. Oncol. 17 4 2000 258 269
15. S.C. Hornyak, K.R. Gehlsen, and T. Haaparanta Histamine dihydrochloride protects against early alcohol-induced liver injury in a rat model Inflammation 27 5 2003 317 327
16. S. Johansson, M. Landstrom, K. Hellstrand, and R. Henriksson The response of Dunning R3327 prostatic adenocarcinoma to IL-2, histamine and radiation Br. J. Cancer 77 8 1998 1213 1219
17. M. Johansson, R. Henriksson, A.T. Bergenheim, and L.O. Koskinen Interleukin-2 and histamine in combination inhibit tumour growth and angiogenesis in malignant glioma Br. J. Cancer 83 6 2000 826 832
18. R. Miesel, M. Kurpisz, and H. Kroger Suppression of inflammatory arthritis by simultaneous inhibition of nitric oxide synthase and NADPH oxidase Free Radic. Biol. Med. 20 1 1996 75 81
19. K. Nakagawa, F.N. Miller, D.E. Sims, A.B. Lentsch, M. Miyazaki, and M.J. Edwards Mechanisms of interleukin-2-induced hepatic toxicity Cancer Res. 56 3 1996 507 510
20. S.A. Rosenberg, J.C. Yang, S.L. Topalian, D.J. Schwartzentruber, J.S. Weber, D.R. Parkinson, C.A. Seipp, J.H. Einhorn, and D.E. White Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2 JAMA 271 12 1994 907 913
21. B.E. Seligmann, M.P. Fletcher, and J.I. Gallin Histamine modulation of human neutrophil oxidative metabolism, locomotion, degranulation, and membrane potential changes J. Immunol. 130 4 1983 1902 1909
22. T. Sendo, Y. Kataoka, Y. Takeda, W. Furuta, and R. Oishi Nitric oxide protects against contrast media-increased pulmonary vascular permeability in rats Invest. Radiol. 35 8 2000 472 478
23. W.H. West, K.W. Tauer, J.R. Yannelli, G.D. Marshall, D.W. Orr, G.B. Thurman, and R.K. Oldham Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer N. Engl. J. Med. 316 15 1987 898 905
24. R. Whittington, and D. Faulds Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer Drugs 46 3 1993 446 514